Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR

Kedudukan dalam Saham #36458
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Harga Saham
$1.73
Disegerakkan terakhir: 2025-06-17
Modal Pasaran
$2.55M
Perubahan (1 hari)
-0.29%
Perubahan (1 tahun)
-79.71%
Negara
US
Perdagangan Eiger BioPharmaceuticals, Inc. (EIGR)

Kategori

Healthcare
Sejarah pecahan saham untuk Eiger BioPharmaceuticals, Inc. (EIGR)
Saham Eiger BioPharmaceuticals, Inc. (simbol: EIGR) telah mengalami sejumlah 2 pecahan saham.
Pecahan saham terkini berlaku pada Jan 08, 2024.
Satu saham EIGR yang dibeli sebelum Mar 23, 2016 kini bersamaan dengan 0.0022222222222222 saham EIGR.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
2024-01-08 1:30 x0.033333333333333 x0.0022222222222222
2016-03-23 1:15 x0.066666666666667 x0.066666666666667
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL